Filgotinib in Moderate to Severe Rheumatoid Arthritis in a Real-World Setting: Up to 6-Month Effectiveness, Patient-Reported Outcomes, and Persistence, and up to 24-Month Safety from More than 1400 Patients in the FILOSOPHY and PARROTFISH Studies

Gerd R. Burmester, James Galloway, Karen Bevers, Jérôme Avouac, Susana Romero-Yuste, Roberto F. Caporali, Neil Betteridge, Carole Van der Donckt, Thomas P. A. Debray, Ouafia Tandjaoui Bouzid, Patrick Verschueren · 2026

Read Filgotinib in Moderate to Severe Rheumatoid Arthritis in a Real-World Setting: Up to 6-Month Effectiveness, Patient-Reported Outcomes, and Persistence, and up to 24-Month Safety from More than 1400 Patients in the FILOSOPHY and PARROTFISH Studies by Gerd R. Burmester, James Galloway, Karen Bevers, Jérôme Avouac, Susana Romero-Yuste, Roberto F. Caporali, Neil Betteridge, Carole Van der Donckt, Thomas P. A. Debray, Ouafia Tandjaoui Bouzid, Patrick Verschueren (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13624248.txt.

Description

Burmester and colleagues reported in 2026 interim results from two large European real-world studies of filgotinib. The once-daily pill treats moderate to severe rheumatoid arthritis, and the studies covered more than fourteen hundred patients. The studies tracked disease activity, patient reports, persistence, and safety for up to two years.

Joint scores improved from the first month, and by six months about seven in ten patients had reached low disease activity. Meaningful relief of pain and fatigue appeared within the first week for many and grew by month six. About eighty-four in a hundred patients were still on the drug at six months. Side effect rates matched past experience, with no new safety signals.

Catalog record

CREATORGerd R. Burmester, James Galloway, Karen Bevers, Jérôme Avouac, Susana Romero-Yuste, Roberto F. Caporali, Neil Betteridge, Carole Van der Donckt, Thomas P. A. Debray, Ouafia Tandjaoui Bouzid, Patrick Verschueren
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE60 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13624248

Browse the full library · About the Tower of Babel